West Pharmaceutical Services (WST) Gross Profit (2009 - 2026)

West Pharmaceutical Services has disclosed Gross Profit across 18 years of filings, most recently posting $296.4 million for Q1 2026.

• Gross Profit for Q1 2026 came in at $296.4 million, up 27.81% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.2 billion (up 16.83% YoY), and the FY2025 annual result was $1.1 billion, up 10.57% from the prior year.
• Gross Profit came in at $296.4 million for Q1 2026 at West Pharmaceutical Services, down from $303.9 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $321.5 million in Q2 2022 to a low of $230.0 million in Q2 2024.
• The 5-year median for Gross Profit is $273.9 million (2025), against an average of $274.4 million.
• Across the five-year window, Gross Profit dropped 21.07% in 2024 and grew 27.81% in 2026, its largest moves.
• West Pharmaceutical Services' Gross Profit stood at $262.1 million in 2022, then advanced by 6.14% to $278.2 million in 2023, then dropped by 1.65% to $273.6 million in 2024, then gained by 11.07% to $303.9 million in 2025, then declined by 2.47% to $296.4 million in 2026.
• The last three Gross Profit figures came in at $296.4 million (Q1 2026), $303.9 million (Q4 2025), and $294.3 million (Q3 2025), per Business Quant data.